Co-ordination of hepatic and adipose tissue lipid metabolism after oral glucose.
The integration of lipid metabolism in the splanchnic bed and in subcutaneous adipose tissue before and after ingestion of a 75 g glucose load was studied by Fick's principle in seven healthy subjects. Six additional subjects were studied during a hyperinsulinemic euglycemic clamp. Release of non-esterified fatty acids (NEFA) from adipose tissue and splanchnic NEFA extraction followed a similar time-course after oral glucose, and there was a highly significant relationship between adipose tissue NEFA release and splanchnic NEFA uptake. There was no immediate inhibition of splanchnic very low density lipoprotein (VLDL)-triacylglycerol (TAG) output when plasma insulin levels increased after glucose. Adipose tissue extraction of VLDL-TAG tended to vary in time in a manner similar to splanchnic VLDL-TAG output and the two were significantly related. The area-under-curves (AUC) for splanchnic extraction of NEFA was significantly lower than that for output of VLDL, implying depletion of hepatic TAG stores during the experiment. In the hyperinsulinemic clamp experiments, there was on average suppression of splanchnic VLDL-TAG output although between-person variability was marked. This suppression could be explained by a very low supply of NEFA during the clamp. We conclude that there is an integrated pattern of metabolism in splanchnic and adipose tissues in the postabsorptive and post-glucose states. Flux of NEFA from adipose tissue drives splanchnic NEFA uptake. Splanchnic VLDL-TAG secretion appears to be regulated by a number of factors and in turn controls TAG extraction in adipose tissue. Insulin does not seem to play a key role in the acute regulation of hepatic VLDL metabolism under these particular conditions in vivo.
Bülow
J
J
Department of Clinical Physiology, Bispebjerg Hospital, DK-2400, Copenhagen NV, Denmark.
Simonsen
L
L
Wiggins
D
D
Humphreys
S M
SM
Frayn
K N
KN
Powell
D
D
Gibbons
G F
GF
D000273:Adipose Tissue / Q000378:metabolism*; D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000008:administration & dosage* / Q000494:pharmacology; D015309:Glucose Clamp Technique; D006801:Humans; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D007657:Ketone Bodies / Q000378:metabolism; D050356:Lipid Metabolism; D008066:Lipolysis / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D013152:Splanchnic Circulation; D014781:Viscera / Q000378:metabolism
D001786:Blood Glucose; D005227:Fatty Acids; D007328:Insulin; D007657:Ketone Bodies; D008079:Lipoproteins, VLDL; D008071:Lipoprotein Lipase; D005947:Glucose